Tag Archives: Novavax

The EVP, CBO and CFO of Novavax is Exercising Options

On August 20 it was reported that the EVP, CBO and CFO of Novavax (NVAX – Research Report), John Trizzino, exercised options to sell 42,788 NVAX shares at $50.94 a share, for a total transaction value of $6.37M. Following John

Analysts Offer Insights on Healthcare Companies: Novavax (NASDAQ: NVAX), Fortress Biotech (NASDAQ: FBIO) and Proteostasis Therapeutics (NASDAQ: PTI)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Novavax (NVAX – Research Report), Fortress Biotech (FBIO – Research Report) and Proteostasis Therapeutics (PTI – Research Report) with bullish sentiments. Novavax

Novavax (NVAX) Receives a Buy from B.Riley FBR

In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Novavax (NVAX – Research Report), with a price target of $184.00. The company’s shares closed last Friday at $145.13, close to its 52-week high of

Novavax (NVAX) was Downgraded to a Hold Rating at Ladenburg Thalmann & Co.

Novavax (NVAX – Research Report) received a Hold rating and a $105.00 price target from Ladenburg Thalmann & Co. analyst Michael Higgins today. The company’s shares closed last Tuesday at $104.56, close to its 52-week high of $111.77. According to

The SVP & GC of Novavax is Exercising Options

Today it was reported that the SVP & GC of Novavax (NVAX – Research Report), John Herrmann, exercised options to sell 12,961 NVAX shares at $26.18 a share, for a total transaction value of $640.8K. Following John Herrmann’s last NVAX

Analysts’ Top Healthcare Picks: Novavax (NVAX), Halozyme (HALO)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Novavax (NVAX – Research Report), Halozyme (HALO – Research Report) and Bluebird Bio (BLUE – Research Report) with bullish sentiments. Novavax (NVAX)